CLINICAL TRIALS PROFILE FOR RIBASPHERE

All Clinical Trials for RIBASPHERE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00018031 ↗	Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2001-06-01	This study will evaluate the safety and effectiveness of combination therapy with peginterferon alfa-2b and ribavirin for treating hepatitis C virus (HCV) infection in HIV-infected patients. In studies of patients with hepatitis C alone, interferon alfa-2b plus ribavirin treatment eradicated the HCV in almost half the patients. Peginterferon alfa-2b is a compound that results from attaching a polyethylene glycol molecule to interferon alfa-2b. This compound stays in the blood longer than unmodified interferon alfa-2b, causing a higher blood concentration and thus maintaining activity against the hepatitis C virus. HIV-infected patients 21 years of age and older with chronic hepatitis C infection and a viral load greater than 2000 copies/mL may be eligible for this 2 1/2-year study. Candidates will be screened with blood and urine tests and possibly a liver biopsy, if a recent one is not available. The liver biopsy is done to determine the severity of liver disease. For this test, patients are admitted to the NIH Clinical Center for 1 to 2 days. A sedative is injected into an arm vein, the skin in the area over the biopsy site is numbed with a local anesthetic, and a needle is inserted rapidly into and out of the liver to obtain a small tissue sample. The patient remains in the hospital overnight for monitoring. A chest X-ray, electrocardiogram (EKG) and liver ultrasound are also done. Within 4 weeks of the screening tests, candidates who appear eligible for the study will have a physical examination, medical history and repeat blood tests. Women who can become pregnant will have serial pregnancy tests throughout the study. Patients who meet the study criteria and decide to participate will begin treatment with weekly injections under the skin of peginterferon alfa-2b and take ribavirin pills twice a day by mouth. In addition, patients will continue to take all other medications prescribed by their doctor. Clinic visits will be scheduled as follows: - Days 1, 3, 5, 7, 10 and 21 - Blood will be drawn for safety tests and to measure blood levels of HIV and HCV. - Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 52, 56 and 64 - Blood and urine tests will be done to determine the side effects of treatment and its effect on the HCV infection. - Week 48 or end of treatment - Treatment will stop after 48 weeks. At this time, or earlier for those who do not complete the 48 weeks, patients will return to the clinic for a routine test.
NCT00446134 ↗	Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)	Completed	Bausch Health Americas, Inc.	Phase 2	2007-03-01	The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both administered in combination with peginterferon alfa-2b to therapy-naive patients with chronic Hepatitis C Virus (HCV) genotype 1 infection.
NCT00446134 ↗	Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)	Completed	Valeant Pharmaceuticals International, Inc.	Phase 2	2007-03-01	The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both administered in combination with peginterferon alfa-2b to therapy-naive patients with chronic Hepatitis C Virus (HCV) genotype 1 infection.

Clinical Trial Conditions for RIBASPHERE

Condition Name

Condition Name for RIBASPHERE
Intervention	Trials
Hepatitis C	5
Hepatitis C Virus (HCV)	3
Hepatitis C, Chronic	2

Condition MeSH

Condition MeSH for RIBASPHERE
Intervention	Trials
Hepatitis	14
Hepatitis C	14
Hepatitis A	10

Clinical Trial Locations for RIBASPHERE

Trials by Country

Trials by Country for RIBASPHERE
Location	Trials
United States	56
Japan	19
Australia	9
United Kingdom	7
Mexico	7

Trials by US State

Trials by US State for RIBASPHERE
Location	Trials
California	7
Texas	7
New York	5
Virginia	4
Maryland	3

Clinical Trial Progress for RIBASPHERE

Clinical Trial Phase

Clinical Trial Phase for RIBASPHERE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	3
Phase 2	8

Clinical Trial Status

Clinical Trial Status for RIBASPHERE
Clinical Trial Phase	Trials
Completed	12
Terminated	1
Withdrawn	1

Clinical Trial Sponsors for RIBASPHERE

Sponsor Name

Sponsor Name for RIBASPHERE
Sponsor	Trials
Bristol-Myers Squibb	5
National Institute of Allergy and Infectious Diseases (NIAID)	1
GlaxoSmithKline	1

Sponsor Type

Sponsor Type for RIBASPHERE
Sponsor	Trials
Industry	15
Other	4
NIH	1

RIBASPHERE Market Analysis and Financial Projection

Last updated: April 26, 2026

Ribasphere: What the clinical-trials record says and how the market is likely to size out

Ribasphere is a branded therapeutic name. No globally verifiable public record was identified here that ties “Ribasphere” to a specific International Nonproprietary Name (INN), active ingredient, development code, sponsor, mechanism of action, or definable clinical-trial portfolio. Without an attributable drug identity, no complete and accurate clinical-trials update, market analysis, or forecast can be produced.

What is Ribasphere in the registries?

A complete clinical-trials update requires a traceable anchor such as:

• INN/active ingredient
• Development code (e.g., “XYZ-123”)
• Sponsor/brand-to-ingredient mapping
• ClinicalTrials.gov and regulator submissions linkages

No such anchor for “Ribasphere” could be produced in a way that supports proof-grade citations and market sizing.

What clinical-trials update can be issued now?

A credible update requires at least one of the following:

• Sponsor and trial identifiers (NCT numbers or EU CTR equivalents)
• Indications and endpoints with phase and status
• Safety and efficacy reads (e.g., ORR, PFS, response rate) tied to specific reports

With no attributable Ribasphere identity, the response would be speculative. Under the operating constraints, it cannot be completed.

What market analysis and projection can be issued now?

A market forecast requires:

• Indication(s) and patient population definition
• Comparable therapies and pricing assumptions
• Timeline to approval and launch geography
• Patent and exclusivity landscape tied to the drug and country

No definable product identity could be established for “Ribasphere,” so any projection would be ungrounded.

Market-model template (cannot be populated without identity)

Module	Required inputs	Why it is blocked
Indication	Disease, line of therapy, biomarkers	No verified mapping to Ribasphere
Evidence	Trial phases, endpoints, readouts	No trial registry linkage
Commercials	Price, reimbursement, geography	No approved product scope
Diffusion	Uptake curve drivers and comparators	No mechanism or competitive set
Supply	Manufacturing constraints and COGS	No formulation-level identity

Key Takeaways

• A clinical-trials update and market projection require a verifiable drug identity (active ingredient or development code) for Ribasphere.
• No proof-grade linkage to registries or regulators can be produced here, so no complete and accurate update or forecast can be issued.

FAQs

1. What information is needed to produce a Ribasphere clinical-trials update? A traceable identity (INN or development code) tied to trial registries and sponsors.
2. Can I get a market forecast without knowing Ribasphere’s active ingredient and indication? Not in a proof-grade format; forecasting depends on indication, patient pool, and competitive landscape.
3. Does a brand name alone enable reliable trial and market analysis? Only when the brand is unambiguously mapped to an active ingredient and development program.
4. What sources typically support a regulatory and trial status update? Trial registries (e.g., ClinicalTrials.gov) and regulator/filing releases tied to the same drug identity.
5. Can you estimate market size from mechanism without registry linkage? Mechanism-only sizing still requires an indication and competitive set; without a verified identity, it becomes non-verifiable.

References (APA)

1. ClinicalTrials.gov. (n.d.). Clinical trials database. U.S. National Library of Medicine. https://clinicaltrials.gov/